Add to ORKGdisease (COPD) [1–4]. While a decrease in mortality was observed for tiotropium HandiHaler ® versus placebo sis w
The effectiveness of the tiotropium Respimat® formulation in routine clinical practice is still an o...
acerbations in patients with chronic obstructive pulmonary disease (COPD) [1-3]. Two formulations ha...
makes a speculative recommendation that tiotropium Respimat should not be pre-scribed in the treatme...
Background Tiotropium delivered at a dose of 5 μg with the Respimat inhaler showed efficacy simila...
INTRODUCTION: Tiotropium is prescribed for the treatment of chronic obstructive pulmonary disease (C...
David MG Halpin,1 Ronald Dahl,2 Christoph Hallmann,3 Achim Mueller,3 Donald Tashkin4 1NHS SW, Royal ...
Background: Tiotropium has been associated with an increased risk of mortality and/or cardiovascular...
Inhaled therapies reduce risk of chronic obstructive pulmonary disease (COPD) exacerbations, but the...
Tiotropium, a long-acting anticholinergic, is delivered via HandiHaler or via Respimat. Randomised c...
differential effects of tiotropium on mortality in COPD’ We thank Dr Lipworth1 for his response to o...
Eric Bateman1, Dave Singh2, David Smith3, Bernd Disse4, Lesley Towse5, Dan Massey5, Jon Blatchford5,...
Steven Kesten1, Bart Celli2, Marc Decramer3, Inge Leimer4, Donald Tashkin51Boehringer Ingelheim Phar...
Tiotropium Respimat increases mortality risk. First do no harm. Tiotropium Respimat should not be pr...
The course of COPD is punctuated by acute exacerbations that are associated with an increase in the ...
Tiotropium has been shown to improve lung function, quality of life, and exacerbations and reduce mo...
The effectiveness of the tiotropium Respimat® formulation in routine clinical practice is still an o...
acerbations in patients with chronic obstructive pulmonary disease (COPD) [1-3]. Two formulations ha...
makes a speculative recommendation that tiotropium Respimat should not be pre-scribed in the treatme...
Background Tiotropium delivered at a dose of 5 μg with the Respimat inhaler showed efficacy simila...
INTRODUCTION: Tiotropium is prescribed for the treatment of chronic obstructive pulmonary disease (C...
David MG Halpin,1 Ronald Dahl,2 Christoph Hallmann,3 Achim Mueller,3 Donald Tashkin4 1NHS SW, Royal ...
Background: Tiotropium has been associated with an increased risk of mortality and/or cardiovascular...
Inhaled therapies reduce risk of chronic obstructive pulmonary disease (COPD) exacerbations, but the...
Tiotropium, a long-acting anticholinergic, is delivered via HandiHaler or via Respimat. Randomised c...
differential effects of tiotropium on mortality in COPD’ We thank Dr Lipworth1 for his response to o...
Eric Bateman1, Dave Singh2, David Smith3, Bernd Disse4, Lesley Towse5, Dan Massey5, Jon Blatchford5,...
Steven Kesten1, Bart Celli2, Marc Decramer3, Inge Leimer4, Donald Tashkin51Boehringer Ingelheim Phar...
Tiotropium Respimat increases mortality risk. First do no harm. Tiotropium Respimat should not be pr...
The course of COPD is punctuated by acute exacerbations that are associated with an increase in the ...
Tiotropium has been shown to improve lung function, quality of life, and exacerbations and reduce mo...
The effectiveness of the tiotropium Respimat® formulation in routine clinical practice is still an o...
acerbations in patients with chronic obstructive pulmonary disease (COPD) [1-3]. Two formulations ha...
makes a speculative recommendation that tiotropium Respimat should not be pre-scribed in the treatme...